Monopar Therapeutics (MNPR) Current Assets (2016 - 2020)

Monopar Therapeutics' Current Assets history spans 5 years, with the latest figure at $18.1 million for Q3 2020.

  • For Q3 2020, Current Assets rose 254.05% year-over-year to $18.1 million; the TTM value through Sep 2020 reached $18.1 million, up 254.05%, while the annual FY2019 figure was $13.2 million, 82.42% up from the prior year.
  • Current Assets for Q3 2020 was $18.1 million at Monopar Therapeutics, up from $12.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $18.1 million in Q3 2020 and bottomed at $2.1 million in Q4 2016.
  • The 5-year median for Current Assets is $7.9 million (2018), against an average of $8.9 million.
  • The largest annual shift saw Current Assets soared 335.82% in 2017 before it tumbled 35.23% in 2019.
  • A 5-year view of Current Assets shows it stood at $2.1 million in 2016, then skyrocketed by 335.82% to $9.1 million in 2017, then fell by 20.58% to $7.3 million in 2018, then skyrocketed by 82.42% to $13.2 million in 2019, then soared by 36.72% to $18.1 million in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Current Assets are $18.1 million (Q3 2020), $12.7 million (Q2 2020), and $12.7 million (Q1 2020).